The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight by 16% in Asian adults with obesity (BMI ≥25 kg/m2), providing robust evidence for population-specific clinical guidelines and reimbursement policies in South Korea and Thailand.